Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II : In vivo evaluation. / Myschik, Julia; McBurney, Warren T; Hennessy, Tania; Phipps-Green, Amanda; Rades, Thomas; Hook, Sarah.

In: Journal of Drug Targeting, Vol. 16, No. 3, 2008, p. 224-32.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Myschik, J, McBurney, WT, Hennessy, T, Phipps-Green, A, Rades, T & Hook, S 2008, 'Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation', Journal of Drug Targeting, vol. 16, no. 3, pp. 224-32. https://doi.org/10.1080/10611860701848886

APA

Myschik, J., McBurney, W. T., Hennessy, T., Phipps-Green, A., Rades, T., & Hook, S. (2008). Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation. Journal of Drug Targeting, 16(3), 224-32. https://doi.org/10.1080/10611860701848886

Vancouver

Myschik J, McBurney WT, Hennessy T, Phipps-Green A, Rades T, Hook S. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation. Journal of Drug Targeting. 2008;16(3):224-32. https://doi.org/10.1080/10611860701848886

Author

Myschik, Julia ; McBurney, Warren T ; Hennessy, Tania ; Phipps-Green, Amanda ; Rades, Thomas ; Hook, Sarah. / Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II : In vivo evaluation. In: Journal of Drug Targeting. 2008 ; Vol. 16, No. 3. pp. 224-32.

Bibtex

@article{c0cf8d93dbea44dfa7473a999b9403f6,
title = "Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation",
abstract = "Sustained-release formulations have drawn the attention of formulation scientists working in the area of vaccine research because these systems may reduce the need for booster immunisations. This would be of great advantage especially for the administration of subunit vaccines. The aim of this study was to illustrate the performance of liposome-forming, sustained-release lipid implants containing 2% of the adjuvant Quil-A (QA) (w/w of total lipids) and ovalbumin (OVA) as a model antigen, in an in vivo study using C57Bl/6 mice. QA/OVA-containing lipid implants were administered subcutaneously and stimulated a similar magnitude of immune response when compared with an immediate-release formulation that contained an equivalent amount of adjuvant and antigen but was administered twice. The novel implant system presented here combines the advantages of both sustained release and particulate delivery in one formulation.",
author = "Julia Myschik and McBurney, {Warren T} and Tania Hennessy and Amanda Phipps-Green and Thomas Rades and Sarah Hook",
year = "2008",
doi = "10.1080/10611860701848886",
language = "English",
volume = "16",
pages = "224--32",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II

T2 - In vivo evaluation

AU - Myschik, Julia

AU - McBurney, Warren T

AU - Hennessy, Tania

AU - Phipps-Green, Amanda

AU - Rades, Thomas

AU - Hook, Sarah

PY - 2008

Y1 - 2008

N2 - Sustained-release formulations have drawn the attention of formulation scientists working in the area of vaccine research because these systems may reduce the need for booster immunisations. This would be of great advantage especially for the administration of subunit vaccines. The aim of this study was to illustrate the performance of liposome-forming, sustained-release lipid implants containing 2% of the adjuvant Quil-A (QA) (w/w of total lipids) and ovalbumin (OVA) as a model antigen, in an in vivo study using C57Bl/6 mice. QA/OVA-containing lipid implants were administered subcutaneously and stimulated a similar magnitude of immune response when compared with an immediate-release formulation that contained an equivalent amount of adjuvant and antigen but was administered twice. The novel implant system presented here combines the advantages of both sustained release and particulate delivery in one formulation.

AB - Sustained-release formulations have drawn the attention of formulation scientists working in the area of vaccine research because these systems may reduce the need for booster immunisations. This would be of great advantage especially for the administration of subunit vaccines. The aim of this study was to illustrate the performance of liposome-forming, sustained-release lipid implants containing 2% of the adjuvant Quil-A (QA) (w/w of total lipids) and ovalbumin (OVA) as a model antigen, in an in vivo study using C57Bl/6 mice. QA/OVA-containing lipid implants were administered subcutaneously and stimulated a similar magnitude of immune response when compared with an immediate-release formulation that contained an equivalent amount of adjuvant and antigen but was administered twice. The novel implant system presented here combines the advantages of both sustained release and particulate delivery in one formulation.

U2 - 10.1080/10611860701848886

DO - 10.1080/10611860701848886

M3 - Journal article

C2 - 18365884

VL - 16

SP - 224

EP - 232

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 3

ER -

ID: 40353499